ReviewCellular immunology2007
New concepts of complement in allorecognition and graft rejection.
Review in Cellular immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.Neuronal signaling · 2021Review
- Engraftment potential of maternal adipose-derived stem cells for fetal transplantation.Heliyon · 2020Article
- Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003.Transplantation · 2017Article
- Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System.Stem cells translational medicine · 2017Review
- SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis.Scientific reports · 2016Article
- Oviduct-Embryo Interactions in Cattle: Two-Way Traffic or a One-Way Street?Biology of reproduction · 2015Article
- The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.Trends in molecular medicine · 2015Review
- Memory B cells in transplantation.Transplantation · 2015Review
- Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats.PloS one · 2015Article
- Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential.Frontiers in immunology · 2014Review
- Article
- Chronic alloantibody mediated rejection.Seminars in immunology · 2012Review
- A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischemic necrosis than Celsior in early cardiac allograft biopsy specimens.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2012Article
- Red blood cell age and potentiation of transfusion-related pathology in trauma patients.Transfusion · 2011Article
- Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2010Article
- Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre.Canadian journal of surgery. Journal canadien de chirurgie · 2010Article
- Endothelial cells in allograft rejection.Transplantation · 2008Review
- New concepts in alloimmune recognition.Cellular immunology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
In transplantation, activation of complement has largely been equated to antibody-mediated rejection, but complement is also important in recognition of apoptotic and necrotic cells as well as in modifying antigen presentation to T cells and B cells. As a part of the innate immune system, complement is one of the first responses to injury, and it can determine the direction and magnitude of the subsequent responses. Consequently, the effects of complement in allorecognition and graft rejection are increased when organs are procured from cadaver donors because these organs sustain a series of stresses from brain death, prolonged life support, ischemia and finally reperfusion that initiate proinflammatory processes and tissue injury. In addition, these organs are transplanted to patients, who frequently have been sensitized to histocompatibility antigens as the result of transfusions, pregnancies or transplants. Complement activation generates a series of biologically active effector molecules that can modulate graft rejection by directly binding to the graft or by modifying the response of macrophages, T and B cells of the recipient. However, complement is regulated and the process of regulation produces split products that can decrease as well as increase immune responses. Small animal models have been developed to test these variables. The guide for evaluating results from these models remains clinical findings because there are significant differences between the rodent and human complement systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.